ClearSky Medical Diagnostics tackles complex medical problems like Parkinson’s and dementia with a fresh approach by applying its specialized “white-box” machine learning algorithms to measure and analyse movement biomarkers, ranging from hand movements to eye saccades.
ClearSky Medical Diagnostics was founded by the University of York and Prof. Stephen Smith with the aim of leveraging their extensive research in evolutionary algorithms to develop digital solutions for neurodegenerative diseases such as Parkinson's Disease, Huntington's Disease, and dementia.
We have collaborated with renowned medical centres and specialists globally, resulting in the development of clinically validated devices. These non-invasive devices provide objective measurements, making them valuable tools for both clinical diagnostics and research studies, addressing the current need for reliable and objective assessment methods.
MAAB is a family-owned business specialising in the investment and international trade of healthcare products. MAAB is trying to bring these innovative technologies into New Zealand and for that, we are eager to work with businesses and healthcare professionals with shared passion to make a difference in patients’ lives.
Professor Stephen Smith, Founder of ClearSky
Prof Stephen Smith
ClearSky’s co-founder and director, is currently a Professor in the Department of Electronic Engineering at the University of York, has a BSc in Computer Science, an MSc (by Research) and PhD in Electronic Engineering . His research has always been concerned with the application of computers to problems in healthcare.
Professor Stephen Smith and his research group have been named ‘national lifesaver’ on the MadeAtUni list of the top 100 University researchers in recognition of his research into the diagnosis and treatment of Parkinson’s.
Professor Smith and collaborators from Leeds General Infirmary have developed the LID-Monitor, which have the potential to greatly improve the quality of data medical staff can access when prescribing medication or assessing the progression of Parkinson’s.